PRNewsWire
23 Sept 2025, 12:01 UTC · 51w ago
Verdict
Headline takes no side. We score MYGN +0.80 across three claims — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Myriad Genetics and SOPHiA GENETICS have entered a strategic collaboration to develop and provide a global liquid biopsy companion diagnostic (CDx) test for pharmaceutical companies.
More positive than 84% of claims this week
The partnership will utilize a hybrid regulatory model where Myriad pursues U.S. submissions and SOPHiA GENETICS manages non-U.S. submissions.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 64% of claims this week
The collaboration will initially focus on converting the MSK-ACCESS liquid biopsy application into a regulated companion diagnostic.
More positive than 53% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Entering a strategic collaboration to develop global liquid biopsy companion diagnostics, expanding its product menu and growth potential.
More positive than 87% of ticker scores this week
Partnering to scale its AI-powered liquid biopsy technology globally and establishing a new hybrid model for companion diagnostics.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Fox Business
1d ago
−50.4%
Price is moving against the score
$3.89 vs $7.84 close before publication (Sep 22) · not market-adjusted
MYGN chart →
